Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

NOVARTIS (NOVN)
Mes dernières consult.
Most popular
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

UK Health Body Approves Novartis's Tasigna For CML

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/25/2012 | 01:16am CEST

The U.K.'s health-cost regulator has decided to back an expensive cancer drug from Novartis AG (NVS) for treating chronic myeloid leukemia--but not one from U.S.-based Bristol-Myers Squibb Co. (BMY)--after the Swiss drug maker offered to cut the drug's price.

The independent National Institute for Clinical Excellence, known by its acronym NICE, said Wednesday it approved Novartis's Tasigna and the company's older drug, whose brand name is Glivec, for use in treating CML on the publicly funded National Health Service. The generic names for Tasigna and Glivec are nilotinib and imatinib, respectively.

However, NICE said it wasn't approving Bristol-Myers Squibb's Sprycel, also known as dasatinib.

CML is a cancer of blood-forming cells in the bone marrow that usually develops slowly, which is why it is described as a chronic form of the disease.

NICE director Carole Longson said: "The recommendations reaffirm the use of imatinib as an effective treatment for the majority of patients and a cost-effective use of NHS resources, and we are also very pleased to be able to add a further treatment option for these patients by recommending nilotinib.

"Although no trials directly comparing dasatinib and nilotinib were available, the committee concluded from indirect comparisons that dasatinib and nilotinib could be considered equally as effective in treating CML.

"However, the manufacturer of nilotinib has already agreed with the Department of Health to provide the drug to the NHS at a discounted price. This reduction in cost enabled the independent committee to approve nilotinib for use on the NHS."

Dasatinib and nilotinib both cost over GBP30,000 per patient a year and the standard dose of imatinib costs GBP20,000.

NICE didn't disclose the price discount offered by Novartis for nilotinib.

-By Sten Stovall, Dow Jones Newswires; +44 207 842 9292; sten.stovall@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVARTIS
08/22 APPLE : Novartis launches first large scale research study in multiple sclerosis..
08/22 NOVARTIS : Erelzi (etanercept), by Sandoz, is now available for patients in Cana..
08/21 NOVARTIS : and Medicines for Malaria Venture launch patient trial in Africa for ..
08/21 NOVARTIS : and Medicines for Malaria Venture launch patient trial in Africa for ..
08/19 NOVARTIS : entices UCSF director to senior position at NIBR
08/17 NOVARTIS : Argentum Pharmaceuticals Succeeds in Starting Patent Cancellation Tri..
08/17 NOVARTIS : Cell Therapy Pioneer David Epstein Expands Role with Rubius Therapeut..
08/17 NEW CHEMICAL RESEARCH STUDY FINDINGS : Exploring Molecular Data Sets Using a Com..
08/17 NOVARTIS : Studies from Novartis Yield New Information about Algorithms (Prelimi..
08/15 NOVARTIS : $87,100 Federal Contract Awarded to Alcon Laboratories
More news
News from SeekingAlpha
08/22 LIGAND : Situated For Growth
08/22 Biotechs in the mix on market's rally
08/22 NOVARTIS : Dividend Aristocrat But Pressure From Generics And Drug Trial Failure..
08/21 OPHTHOTECH : 3 Strikes And It's Out?
08/21 The Troubles Never End For Teva
Financials ($)
Sales 2017 48 668 M
EBIT 2017 11 971 M
Net income 2017 7 307 M
Debt 2017 15 947 M
Yield 2017 3,42%
P/E ratio 2017 23,96
P/E ratio 2018 21,12
EV / Sales 2017 4,84x
EV / Sales 2018 4,63x
Capitalization 219 476 M
Chart NOVARTIS
Duration : Period :
Novartis Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 32
Average target price 87,3 $
Spread / Average Target 4,8%
EPS Revisions
Managers
NameTitle
Joseph Jimenez Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Kirsch Chief Financial Officer
Vasant Narasimhan Chief Medical Officer & Head-Drug Development
Srikant Madhav Datar Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS7.89%219 476
JOHNSON & JOHNSON15.83%358 180
ROCHE HOLDING LTD.3.78%215 061
PFIZER2.06%195 090
MERCK AND COMPANY6.03%169 014
SANOFI6.97%121 990